Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (191-200 of 306) with videos related to

Pageof 31
Sort By:
Oncology|February 23, 2016
Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular CarcinomaHideo Kunimoto, Kenji Ikeda, Yushi Sorin, et al.
Hepatology Communications|May 18, 2022
Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up studyNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Journal of Medical Virology|August 24, 2006
Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and CMariko Kobayashi, Fumitaka Suzuki, Norio Akuta, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 21, 2010
Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancerKenji Ikeda, Masahiro Kobayashi, Yuya Seko, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 5, 2011
Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov modelKenji Ikeda, Masahiro Kobayashi, Yusuke Kawamura, et al.
Intervirology|April 7, 2005
Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatmentNorio Akuta, Fumitaka Suzuki, Mariko Kobayashi, et al.
Intervirology|March 4, 2010
Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 casesNorio Akuta, Fumitaka Suzuki, Yasuji Arase, et al.
Journal of Gastroenterology and Hepatology|February 20, 2009
Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?Yoshiyuki Suzuki, Fumitaka Suzuki, Yusuke Kawamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 1, 2009
Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutantsTetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, et al.
Internal Medicine (Tokyo, Japan)|August 19, 2009
The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2Yasuji Arase, Fumitaka Suzuki, Hitomi Sezaki, et al.
Pageof 31

Showing results (191-200 of 306) with videos related to

Sort By:
Pageof 31
Oncology|February 23, 2016
Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular CarcinomaHideo Kunimoto, Kenji Ikeda, Yushi Sorin, et al.
Hepatology Communications|May 18, 2022
Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up studyNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Journal of Medical Virology|August 24, 2006
Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and CMariko Kobayashi, Fumitaka Suzuki, Norio Akuta, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 21, 2010
Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancerKenji Ikeda, Masahiro Kobayashi, Yuya Seko, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 5, 2011
Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov modelKenji Ikeda, Masahiro Kobayashi, Yusuke Kawamura, et al.
Intervirology|April 7, 2005
Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatmentNorio Akuta, Fumitaka Suzuki, Mariko Kobayashi, et al.
Intervirology|March 4, 2010
Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 casesNorio Akuta, Fumitaka Suzuki, Yasuji Arase, et al.
Journal of Gastroenterology and Hepatology|February 20, 2009
Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?Yoshiyuki Suzuki, Fumitaka Suzuki, Yusuke Kawamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 1, 2009
Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutantsTetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, et al.
Internal Medicine (Tokyo, Japan)|August 19, 2009
The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2Yasuji Arase, Fumitaka Suzuki, Hitomi Sezaki, et al.
Pageof 31